General drug use-results survey of UPASITA IV Injection Syringe for Dialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2041210113

Enrollment

770

Registered

2021-12-17

Start date

2022-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism under hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with secondary hyperparathyroidism under hemodialysis who are using this drug for the first time

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of onset of hypocalcaemia Incidence of onset of QT prolonged Incidence of onset of bone metabolism disorder	—

Contacts

Public ContactPharmacovigilance Dept.

Sanwa Kagaku Kenkyusho Co., Ltd.

pms@ml.skk-net.com+81-52-951-8167

Outcome results